ID LTBP2_HUMAN Reviewed; 1821 AA. AC Q14767; Q99907; Q9NS51; DT 16-JAN-2004, integrated into UniProtKB/Swiss-Prot. DT 18-MAY-2010, sequence version 3. DT 27-MAR-2024, entry version 200. DE RecName: Full=Latent-transforming growth factor beta-binding protein 2; DE Short=LTBP-2; DE Flags: Precursor; GN Name=LTBP2; Synonyms=C14orf141, LTBP3; OS Homo sapiens (Human). OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; OC Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae; OC Homo. OX NCBI_TaxID=9606; RN [1] RP NUCLEOTIDE SEQUENCE [MRNA], COMPLEX FORMATION WITH TGFB1, SUBCELLULAR RP LOCATION, AND TISSUE SPECIFICITY. RC TISSUE=Foreskin fibroblast; RX PubMed=7798248; DOI=10.1016/s0021-9258(18)31659-4; RA Moren A., Olofsson A., Stenman G., Sahlin P., Kanzaki T., RA Claesson-Welsh L., ten Dijke P., Miyazono K., Heldin C.; RT "Identification and characterization of LTBP-2, a novel latent transforming RT growth factor-beta-binding protein."; RL J. Biol. Chem. 269:32469-32478(1994). RN [2] RP NUCLEOTIDE SEQUENCE [MRNA]. RX PubMed=8697098; DOI=10.1016/1357-2725(95)00167-0; RA Bashir M.M., Han M.-D., Abrams W.R., Tucker T., Ma R.-I., Gibson M., RA Ritty T., Mecham R., Rosenbloom J.; RT "Analysis of the human gene encoding latent transforming growth factor- RT beta-binding protein-2."; RL Int. J. Biochem. Cell Biol. 28:531-542(1996). RN [3] RP NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA]. RX PubMed=12508121; DOI=10.1038/nature01348; RA Heilig R., Eckenberg R., Petit J.-L., Fonknechten N., Da Silva C., RA Cattolico L., Levy M., Barbe V., De Berardinis V., Ureta-Vidal A., RA Pelletier E., Vico V., Anthouard V., Rowen L., Madan A., Qin S., Sun H., RA Du H., Pepin K., Artiguenave F., Robert C., Cruaud C., Bruels T., RA Jaillon O., Friedlander L., Samson G., Brottier P., Cure S., Segurens B., RA Aniere F., Samain S., Crespeau H., Abbasi N., Aiach N., Boscus D., RA Dickhoff R., Dors M., Dubois I., Friedman C., Gouyvenoux M., James R., RA Madan A., Mairey-Estrada B., Mangenot S., Martins N., Menard M., Oztas S., RA Ratcliffe A., Shaffer T., Trask B., Vacherie B., Bellemere C., Belser C., RA Besnard-Gonnet M., Bartol-Mavel D., Boutard M., Briez-Silla S., RA Combette S., Dufosse-Laurent V., Ferron C., Lechaplais C., Louesse C., RA Muselet D., Magdelenat G., Pateau E., Petit E., Sirvain-Trukniewicz P., RA Trybou A., Vega-Czarny N., Bataille E., Bluet E., Bordelais I., Dubois M., RA Dumont C., Guerin T., Haffray S., Hammadi R., Muanga J., Pellouin V., RA Robert D., Wunderle E., Gauguet G., Roy A., Sainte-Marthe L., Verdier J., RA Verdier-Discala C., Hillier L.W., Fulton L., McPherson J., Matsuda F., RA Wilson R., Scarpelli C., Gyapay G., Wincker P., Saurin W., Quetier F., RA Waterston R., Hood L., Weissenbach J.; RT "The DNA sequence and analysis of human chromosome 14."; RL Nature 421:601-607(2003). RN [4] RP LACK OF INTERACTION WITH TGFB1, AND MUTAGENESIS OF 1449-ASP-LEU-1450. RX PubMed=10930463; DOI=10.1091/mbc.11.8.2691; RA Saharinen J., Keski-Oja J.; RT "Specific sequence motif of 8-Cys repeats of TGF-beta binding proteins, RT LTBPs, creates a hydrophobic interaction surface for binding of small RT latent TGF-beta."; RL Mol. Biol. Cell 11:2691-2704(2000). RN [5] RP REVIEW. RX PubMed=10743502; DOI=10.1016/s1359-6101(99)00010-6; RA Saharinen J., Hyytiainen M., Taipale J., Keski-Oja J.; RT "Latent transforming growth factor-beta binding proteins (LTBPs) RT -- structural extracellular matrix proteins for targeting TGF-beta RT action."; RL Cytokine Growth Factor Rev. 10:99-117(1999). RN [6] RP REVIEW. RX PubMed=11104663; DOI=10.1042/bj3520601; RA Oklu R., Hesketh R.; RT "The latent transforming growth factor beta binding protein (LTBP) RT family."; RL Biochem. J. 352:601-610(2000). RN [7] RP INTERACTION WITH FBN1, GLYCOSYLATION, TISSUE SPECIFICITY, AND C-TERMINAL RP REGION DOMAIN. RX PubMed=17293099; DOI=10.1016/j.matbio.2006.12.006; RA Hirani R., Hanssen E., Gibson M.A.; RT "LTBP-2 specifically interacts with the amino-terminal region of fibrillin- RT 1 and competes with LTBP-1 for binding to this microfibrillar protein."; RL Matrix Biol. 26:213-223(2007). RN [8] RP INVOLVEMENT IN GLC3D. RX PubMed=19361779; DOI=10.1016/j.ajhg.2009.03.017; RA Ali M., McKibbin M., Booth A., Parry D.A., Jain P., Riazuddin S.A., RA Hejtmancik J.F., Khan S.N., Firasat S., Shires M., Gilmour D.F., Towns K., RA Murphy A.L., Azmanov D., Tournev I., Cherninkova S., Jafri H., Raashid Y., RA Toomes C., Craig J., Mackey D.A., Kalaydjieva L., Riazuddin S., RA Inglehearn C.F.; RT "Null mutations in LTBP2 cause primary congenital glaucoma."; RL Am. J. Hum. Genet. 84:664-671(2009). RN [9] RP INVOLVEMENT IN MSPKA. RX PubMed=20617341; DOI=10.1007/s00439-010-0858-8; RA Kumar A., Duvvari M.R., Prabhakaran V.C., Shetty J.S., Murthy G.J., RA Blanton S.H.; RT "A homozygous mutation in LTBP2 causes isolated microspherophakia."; RL Hum. Genet. 128:365-371(2010). RN [10] RP HEPARIN-BINDING REGIONS, AND INTERACTION WITH SDC4. RX PubMed=20382221; DOI=10.1016/j.matbio.2010.03.005; RA Parsi M.K., Adams J.R., Whitelock J., Gibson M.A.; RT "LTBP-2 has multiple heparin/heparan sulfate binding sites."; RL Matrix Biol. 29:393-401(2010). RN [11] RP VARIANT WMS3 MET-1177. RX PubMed=22539340; DOI=10.1002/humu.22105; RA Haji-Seyed-Javadi R., Jelodari-Mamaghani S., Paylakhi S.H., Yazdani S., RA Nilforushan N., Fan J.B., Klotzle B., Mahmoudi M.J., Ebrahimian M.J., RA Chelich N., Taghiabadi E., Kamyab K., Boileau C., Paisan-Ruiz C., RA Ronaghi M., Elahi E.; RT "LTBP2 mutations cause Weill-Marchesani and Weill-Marchesani-like syndrome RT and affect disruptions in the extracellular matrix."; RL Hum. Mutat. 33:1182-1187(2012). CC -!- FUNCTION: May play an integral structural role in elastic-fiber CC architectural organization and/or assembly. CC {ECO:0000303|PubMed:10743502, ECO:0000303|PubMed:11104663}. CC -!- SUBUNIT: Forms part of the large latent transforming growth factor beta CC precursor complex; removal is essential for activation of complex CC (PubMed:7798248). Interacts with SDC4 (PubMed:20382221). Interacts (via CC C-terminal domain) with FBN1 (via N-terminal domain) in a Ca(+2)- CC dependent manner (PubMed:17293099). {ECO:0000269|PubMed:17293099, CC ECO:0000269|PubMed:20382221, ECO:0000269|PubMed:7798248}. CC -!- INTERACTION: CC Q14767; Q9UBX5: FBLN5; NbExp=2; IntAct=EBI-1546118, EBI-947897; CC -!- SUBCELLULAR LOCATION: Secreted, extracellular space, extracellular CC matrix {ECO:0000269|PubMed:7798248}. CC -!- TISSUE SPECIFICITY: Expressed in the aorta (at protein level). CC Expressed in lung, weakly expressed in heart, placenta, liver and CC skeletal muscle. {ECO:0000269|PubMed:17293099, CC ECO:0000269|PubMed:7798248}. CC -!- PTM: N-Glycosylated. {ECO:0000269|PubMed:17293099}. CC -!- PTM: Contains hydroxylated asparagine residues. CC {ECO:0000250|UniProtKB:Q14766}. CC -!- DISEASE: Glaucoma 3, primary congenital, D (GLC3D) [MIM:613086]: An CC autosomal recessive form of primary congenital glaucoma (PCG). PCG is CC characterized by marked increase of intraocular pressure at birth or CC early childhood, large ocular globes (buphthalmos) and corneal edema. CC It results from developmental defects of the trabecular meshwork and CC anterior chamber angle of the eye that prevent adequate drainage of CC aqueous humor. {ECO:0000269|PubMed:19361779}. Note=The disease is CC caused by variants affecting the gene represented in this entry. CC -!- DISEASE: Microspherophakia and/or megalocornea, with ectopia lentis and CC with or without secondary glaucoma (MSPKA) [MIM:251750]: A rare disease CC characterized by smaller and more spherical lenses than normal CC bilaterally, an increased anteroposterior thickness of the lens, and CC highly myopic eyes. Lens dislocation or subluxation may occur, leading CC to defective accommodation. {ECO:0000269|PubMed:20617341}. Note=The CC disease is caused by variants affecting the gene represented in this CC entry. CC -!- DISEASE: Weill-Marchesani syndrome 3 (WMS3) [MIM:614819]: A rare CC connective tissue disorder characterized by short stature, CC brachydactyly, joint stiffness, and eye abnormalities including CC microspherophakia, ectopia lentis, severe myopia and glaucoma. CC {ECO:0000269|PubMed:22539340}. Note=The disease is caused by variants CC affecting the gene represented in this entry. CC -!- SIMILARITY: Belongs to the LTBP family. {ECO:0000305}. CC -!- CAUTION: A publication reported that a complex is formed with TGFB1 CC (PubMed:7798248). According to another report, there is no association CC with TGFB1 (PubMed:10930463). {ECO:0000269|PubMed:10930463, CC ECO:0000269|PubMed:7798248}. CC --------------------------------------------------------------------------- CC Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms CC Distributed under the Creative Commons Attribution (CC BY 4.0) License CC --------------------------------------------------------------------------- DR EMBL; Z37976; CAA86030.1; -; mRNA. DR EMBL; S82451; AAB37459.1; -; mRNA. DR EMBL; AC013451; AAF87081.1; -; Genomic_DNA. DR CCDS; CCDS9831.1; -. DR PIR; A55494; A55494. DR RefSeq; NP_000419.1; NM_000428.2. DR AlphaFoldDB; Q14767; -. DR BioGRID; 110231; 96. DR IntAct; Q14767; 3. DR MINT; Q14767; -. DR STRING; 9606.ENSP00000261978; -. DR GlyConnect; 1448; 16 N-Linked glycans (3 sites). DR GlyCosmos; Q14767; 28 sites, 21 glycans. DR GlyGen; Q14767; 41 sites, 15 N-linked glycans (3 sites), 8 O-linked glycans (32 sites). DR iPTMnet; Q14767; -. DR PhosphoSitePlus; Q14767; -. DR SwissPalm; Q14767; -. DR BioMuta; LTBP2; -. DR DMDM; 296439311; -. DR EPD; Q14767; -. DR jPOST; Q14767; -. DR MassIVE; Q14767; -. DR PaxDb; 9606-ENSP00000261978; -. DR PeptideAtlas; Q14767; -. DR ProteomicsDB; 60164; -. DR Antibodypedia; 157; 140 antibodies from 23 providers. DR DNASU; 4053; -. DR Ensembl; ENST00000261978.9; ENSP00000261978.4; ENSG00000119681.12. DR GeneID; 4053; -. DR KEGG; hsa:4053; -. DR MANE-Select; ENST00000261978.9; ENSP00000261978.4; NM_000428.3; NP_000419.1. DR UCSC; uc001xqa.4; human. DR AGR; HGNC:6715; -. DR CTD; 4053; -. DR DisGeNET; 4053; -. DR GeneCards; LTBP2; -. DR GeneReviews; LTBP2; -. DR HGNC; HGNC:6715; LTBP2. DR HPA; ENSG00000119681; Low tissue specificity. DR MalaCards; LTBP2; -. DR MIM; 251750; phenotype. DR MIM; 602091; gene. DR MIM; 613086; phenotype. DR MIM; 614819; phenotype. DR neXtProt; NX_Q14767; -. DR OpenTargets; ENSG00000119681; -. DR Orphanet; 98976; Congenital glaucoma. DR Orphanet; 238763; Glaucoma secondary to spherophakia/ectopia lentis and megalocornea. DR Orphanet; 3449; Weill-Marchesani syndrome. DR PharmGKB; PA164741922; -. DR VEuPathDB; HostDB:ENSG00000119681; -. DR eggNOG; KOG1217; Eukaryota. DR GeneTree; ENSGT00940000160884; -. DR HOGENOM; CLU_001884_1_0_1; -. DR InParanoid; Q14767; -. DR OMA; ADPPHCA; -. DR OrthoDB; 354414at2759; -. DR PhylomeDB; Q14767; -. DR PathwayCommons; Q14767; -. DR Reactome; R-HSA-2129379; Molecules associated with elastic fibres. DR Reactome; R-HSA-2173789; TGF-beta receptor signaling activates SMADs. DR SignaLink; Q14767; -. DR SIGNOR; Q14767; -. DR BioGRID-ORCS; 4053; 14 hits in 1138 CRISPR screens. DR ChiTaRS; LTBP2; human. DR GeneWiki; LTBP2; -. DR GenomeRNAi; 4053; -. DR Pharos; Q14767; Tbio. DR PRO; PR:Q14767; -. DR Proteomes; UP000005640; Chromosome 14. DR RNAct; Q14767; Protein. DR Bgee; ENSG00000119681; Expressed in descending thoracic aorta and 198 other cell types or tissues. DR ExpressionAtlas; Q14767; baseline and differential. DR GO; GO:0062023; C:collagen-containing extracellular matrix; HDA:BHF-UCL. DR GO; GO:0070062; C:extracellular exosome; HDA:UniProtKB. DR GO; GO:0031012; C:extracellular matrix; TAS:ProtInc. DR GO; GO:0005576; C:extracellular region; HDA:BHF-UCL. DR GO; GO:0005615; C:extracellular space; HDA:BHF-UCL. DR GO; GO:0005509; F:calcium ion binding; IEA:InterPro. DR GO; GO:0019838; F:growth factor binding; IEA:UniProtKB-KW. DR GO; GO:0008201; F:heparin binding; IEA:UniProtKB-KW. DR GO; GO:0050436; F:microfibril binding; IBA:GO_Central. DR GO; GO:0009306; P:protein secretion; TAS:ProtInc. DR GO; GO:0006605; P:protein targeting; TAS:ProtInc. DR GO; GO:0097435; P:supramolecular fiber organization; IMP:MGI. DR GO; GO:0007179; P:transforming growth factor beta receptor signaling pathway; TAS:ProtInc. DR CDD; cd00054; EGF_CA; 13. DR Gene3D; 2.10.25.10; Laminin; 19. DR Gene3D; 3.90.290.10; TGF-beta binding (TB) domain; 4. DR InterPro; IPR001881; EGF-like_Ca-bd_dom. DR InterPro; IPR000742; EGF-like_dom. DR InterPro; IPR000152; EGF-type_Asp/Asn_hydroxyl_site. DR InterPro; IPR018097; EGF_Ca-bd_CS. DR InterPro; IPR009030; Growth_fac_rcpt_cys_sf. DR InterPro; IPR017878; TB_dom. DR InterPro; IPR036773; TB_dom_sf. DR PANTHER; PTHR24034; EGF-LIKE DOMAIN-CONTAINING PROTEIN; 1. DR PANTHER; PTHR24034:SF166; VACUOLAR-SORTING RECEPTOR 1; 1. DR Pfam; PF00008; EGF; 1. DR Pfam; PF07645; EGF_CA; 17. DR Pfam; PF00683; TB; 4. DR SMART; SM00181; EGF; 20. DR SMART; SM00179; EGF_CA; 18. DR SUPFAM; SSF57196; EGF/Laminin; 6. DR SUPFAM; SSF57184; Growth factor receptor domain; 5. DR SUPFAM; SSF57581; TB module/8-cys domain; 4. DR PROSITE; PS00010; ASX_HYDROXYL; 13. DR PROSITE; PS00022; EGF_1; 2. DR PROSITE; PS01186; EGF_2; 11. DR PROSITE; PS50026; EGF_3; 15. DR PROSITE; PS01187; EGF_CA; 16. DR PROSITE; PS51364; TB; 4. DR Genevisible; Q14767; HS. PE 1: Evidence at protein level; KW Disease variant; Disulfide bond; Dwarfism; EGF-like domain; KW Extracellular matrix; Glaucoma; Glycoprotein; Growth factor binding; KW Heparin-binding; Hydroxylation; Phosphoprotein; Reference proteome; Repeat; KW Secreted; Signal. FT SIGNAL 1..35 FT /evidence="ECO:0000250|UniProtKB:O35806" FT CHAIN 36..1821 FT /note="Latent-transforming growth factor beta-binding FT protein 2" FT /id="PRO_0000007643" FT DOMAIN 187..219 FT /note="EGF-like 1" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00076" FT DOMAIN 396..428 FT /note="EGF-like 2" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00076" FT DOMAIN 552..604 FT /note="TB 1" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00697" FT DOMAIN 622..662 FT /note="EGF-like 3; calcium-binding" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00076" FT DOMAIN 672..724 FT /note="TB 2" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00697" FT DOMAIN 844..886 FT /note="EGF-like 4" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00076" FT DOMAIN 887..929 FT /note="EGF-like 5; calcium-binding" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00076" FT DOMAIN 930..969 FT /note="EGF-like 6; calcium-binding" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00076" FT DOMAIN 970..1009 FT /note="EGF-like 7; calcium-binding" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00076" FT DOMAIN 1010..1050 FT /note="EGF-like 8; calcium-binding" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00076" FT DOMAIN 1051..1092 FT /note="EGF-like 9; calcium-binding" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00076" FT DOMAIN 1093..1134 FT /note="EGF-like 10; calcium-binding" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00076" FT DOMAIN 1135..1175 FT /note="EGF-like 11; calcium-binding" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00076" FT DOMAIN 1176..1217 FT /note="EGF-like 12; calcium-binding" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00076" FT DOMAIN 1218..1258 FT /note="EGF-like 13; calcium-binding" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00076" FT DOMAIN 1259..1302 FT /note="EGF-like 14; calcium-binding" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00076" FT DOMAIN 1303..1344 FT /note="EGF-like 15; calcium-binding" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00076" FT DOMAIN 1345..1387 FT /note="EGF-like 16; calcium-binding" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00076" FT DOMAIN 1411..1463 FT /note="TB 3" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00697" FT DOMAIN 1485..1527 FT /note="EGF-like 17; calcium-binding" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00076" FT DOMAIN 1528..1567 FT /note="EGF-like 18; calcium-binding" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00076" FT DOMAIN 1584..1636 FT /note="TB 4" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00697" FT DOMAIN 1733..1773 FT /note="EGF-like 19; calcium-binding" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00076" FT DOMAIN 1774..1818 FT /note="EGF-like 20; calcium-binding" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00076" FT REGION 38..58 FT /note="Disordered" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT REGION 81..165 FT /note="Disordered" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT REGION 94..115 FT /note="Heparin-binding" FT REGION 229..339 FT /note="Disordered" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT REGION 232..249 FT /note="Heparin-binding" FT REGION 510..544 FT /note="Disordered" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT REGION 744..772 FT /note="Disordered" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT REGION 1639..1821 FT /note="C-terminal domain" FT /evidence="ECO:0000269|PubMed:17293099" FT MOTIF 375..377 FT /note="Cell attachment site" FT /evidence="ECO:0000255" FT COMPBIAS 110..132 FT /note="Polar residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 276..316 FT /note="Polar residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT BINDING 344..354 FT /ligand="heparin" FT /ligand_id="ChEBI:CHEBI:28304" FT MOD_RES 506 FT /note="Phosphoserine" FT /evidence="ECO:0000250|UniProtKB:O08999" FT CARBOHYD 181 FT /note="N-linked (GlcNAc...) asparagine" FT /evidence="ECO:0000255" FT CARBOHYD 343 FT /note="N-linked (GlcNAc...) asparagine" FT /evidence="ECO:0000255" FT CARBOHYD 421 FT /note="N-linked (GlcNAc...) asparagine" FT /evidence="ECO:0000255" FT CARBOHYD 616 FT /note="N-linked (GlcNAc...) asparagine" FT /evidence="ECO:0000255" FT CARBOHYD 811 FT /note="N-linked (GlcNAc...) asparagine" FT /evidence="ECO:0000255" FT CARBOHYD 1170 FT /note="N-linked (GlcNAc...) asparagine" FT /evidence="ECO:0000255" FT CARBOHYD 1309 FT /note="N-linked (GlcNAc...) asparagine" FT /evidence="ECO:0000255" FT CARBOHYD 1430 FT /note="N-linked (GlcNAc...) asparagine" FT /evidence="ECO:0000255" FT CARBOHYD 1568 FT /note="N-linked (GlcNAc...) asparagine" FT /evidence="ECO:0000255" FT DISULFID 191..201 FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00076" FT DISULFID 195..207 FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00076" FT DISULFID 209..218 FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00076" FT DISULFID 400..410 FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00076" FT DISULFID 404..416 FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00076" FT DISULFID 418..427 FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00076" FT DISULFID 554..576 FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00697" FT DISULFID 563..589 FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00697" FT DISULFID 577..592 FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00697" FT DISULFID 626..637 FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00076" FT DISULFID 632..646 FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00076" FT DISULFID 648..661 FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00076" FT DISULFID 674..696 FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00697" FT DISULFID 683..709 FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00697" FT DISULFID 697..712 FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00697" FT DISULFID 698..724 FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00697" FT DISULFID 848..861 FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00076" FT DISULFID 856..870 FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00076" FT DISULFID 872..885 FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00076" FT DISULFID 891..902 FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00076" FT DISULFID 896..911 FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00076" FT DISULFID 913..928 FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00076" FT DISULFID 934..945 FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00076" FT DISULFID 940..954 FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00076" FT DISULFID 956..968 FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00076" FT DISULFID 974..985 FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00076" FT DISULFID 980..994 FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00076" FT DISULFID 997..1008 FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00076" FT DISULFID 1014..1025 FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00076" FT DISULFID 1020..1034 FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00076" FT DISULFID 1036..1049 FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00076" FT DISULFID 1055..1066 FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00076" FT DISULFID 1061..1075 FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00076" FT DISULFID 1078..1091 FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00076" FT DISULFID 1097..1108 FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00076" FT DISULFID 1103..1117 FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00076" FT DISULFID 1120..1133 FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00076" FT DISULFID 1139..1151 FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00076" FT DISULFID 1146..1160 FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00076" FT DISULFID 1162..1174 FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00076" FT DISULFID 1180..1192 FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00076" FT DISULFID 1186..1201 FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00076" FT DISULFID 1203..1216 FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00076" FT DISULFID 1222..1233 FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00076" FT DISULFID 1228..1242 FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00076" FT DISULFID 1244..1257 FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00076" FT DISULFID 1263..1276 FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00076" FT DISULFID 1271..1285 FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00076" FT DISULFID 1289..1301 FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00076" FT DISULFID 1307..1319 FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00076" FT DISULFID 1313..1328 FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00076" FT DISULFID 1330..1343 FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00076" FT DISULFID 1349..1361 FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00076" FT DISULFID 1356..1370 FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00076" FT DISULFID 1372..1386 FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00076" FT DISULFID 1413..1436 FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00697" FT DISULFID 1423..1448 FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00697" FT DISULFID 1437..1451 FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00697" FT DISULFID 1438..1463 FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00697" FT DISULFID 1489..1502 FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00076" FT DISULFID 1497..1511 FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00076" FT DISULFID 1513..1526 FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00076" FT DISULFID 1532..1542 FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00076" FT DISULFID 1537..1551 FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00076" FT DISULFID 1553..1566 FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00076" FT DISULFID 1586..1609 FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00697" FT DISULFID 1595..1621 FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00697" FT DISULFID 1610..1624 FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00697" FT DISULFID 1611..1636 FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00697" FT DISULFID 1737..1748 FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00076" FT DISULFID 1743..1757 FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00076" FT DISULFID 1759..1772 FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00076" FT DISULFID 1778..1793 FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00076" FT DISULFID 1788..1802 FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00076" FT DISULFID 1804..1817 FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00076" FT VARIANT 37 FT /note="R -> M (in dbSNP:rs934996)" FT /id="VAR_059270" FT VARIANT 319 FT /note="P -> Q (in dbSNP:rs2304707)" FT /id="VAR_055752" FT VARIANT 591 FT /note="P -> S (in dbSNP:rs2196862)" FT /id="VAR_060337" FT VARIANT 1177 FT /note="V -> M (in WMS3; dbSNP:rs137854856)" FT /evidence="ECO:0000269|PubMed:22539340" FT /id="VAR_068647" FT MUTAGEN 1449..1450 FT /note="DL->EIFP: Gain-of-function. Forms a complex with FT TGFB1." FT /evidence="ECO:0000269|PubMed:10930463" FT CONFLICT 897 FT /note="K -> Q (in Ref. 1; CAA86030)" FT /evidence="ECO:0000305" FT CONFLICT 1443 FT /note="S -> T (in Ref. 1; CAA86030)" FT /evidence="ECO:0000305" FT CONFLICT 1615 FT /note="E -> K (in Ref. 1; CAA86030)" FT /evidence="ECO:0000305" SQ SEQUENCE 1821 AA; 195052 MW; 3D6952B39885E1A6 CRC64; MRPRTKARSP GRALRNPWRG FLPLTLALFV GAGHAQRDPV GRYEPAGGDA NRLRRPGGSY PAAAAAKVYS LFREQDAPVA GLQPVERAQP GWGSPRRPTE AEARRPSRAQ QSRRVQPPAQ TRRSTPLGQQ QPAPRTRAAP ALPRLGTPQR SGAAPPTPPR GRLTGRNVCG GQCCPGWTTA NSTNHCIKPV CEPPCQNRGS CSRPQLCVCR SGFRGARCEE VIPDEEFDPQ NSRLAPRRWA ERSPNLRRSS AAGEGTLARA QPPAPQSPPA PQSPPAGTLS GLSQTHPSQQ HVGLSRTVRL HPTATASSQL SSNALPPGPG LEQRDGTQQA VPLEHPSSPW GLNLTEKIKK IKIVFTPTIC KQTCARGHCA NSCERGDTTT LYSQGGHGHD PKSGFRIYFC QIPCLNGGRC IGRDECWCPA NSTGKFCHLP IPQPDREPPG RGSRPRALLE APLKQSTFTL PLSNQLASVN PSLVKVHIHH PPEASVQIHQ VAQVRGGVEE ALVENSVETR PPPWLPASPG HSLWDSNNIP ARSGEPPRPL PPAAPRPRGL LGRCYLNTVN GQCANPLLEL TTQEDCCGSV GAFWGVTLCA PCPPRPASPV IENGQLECPQ GYKRLNLTHC QDINECLTLG LCKDAECVNT RGSYLCTCRP GLMLDPSRSR CVSDKAISML QGLCYRSLGP GTCTLPLAQR ITKQICCCSR VGKAWGSECE KCPLPGTEAF REICPAGHGY TYASSDIRLS MRKAEEEELA RPPREQGQRS SGALPGPAER QPLRVVTDTW LEAGTIPDKG DSQAGQVTTS VTHAPAWVTG NATTPPMPEQ GIAEIQEEQV TPSTDVLVTL STPGIDRCAA GATNVCGPGT CVNLPDGYRC VCSPGYQLHP SQAYCTDDNE CLRDPCKGKG RCINRVGSYS CFCYPGYTLA TSGATQECQD INECEQPGVC SGGQCTNTEG SYHCECDQGY IMVRKGHCQD INECRHPGTC PDGRCVNSPG SYTCLACEEG YRGQSGSCVD VNECLTPGVC AHGKCTNLEG SFRCSCEQGY EVTSDEKGCQ DVDECASRAS CPTGLCLNTE GSFACSACEN GYWVNEDGTA CEDLDECAFP GVCPSGVCTN TAGSFSCKDC DGGYRPSPLG DSCEDVDECE DPQSSCLGGE CKNTVGSYQC LCPQGFQLAN GTVCEDVNEC MGEEHCAPHG ECLNSHGSFF CLCAPGFVSA EGGTSCQDVD ECATTDPCVG GHCVNTEGSF NCLCETGFQP SPESGECVDI DECEDYGDPV CGTWKCENSP GSYRCVLGCQ PGFHMAPNGD CIDIDECAND TMCGSHGFCD NTDGSFRCLC DQGFEISPSG WDCVDVNECE LMLAVCGAAL CENVEGSFLC LCASDLEEYD AQEGHCRPRG AGGQSMSEAP TGDHAPAPTR MDCYSGQKGH APCSSVLGRN TTQAECCCTQ GASWGDACDL CPSEDSAEFS EICPSGKGYI PVEGAWTFGQ TMYTDADECV IFGPGLCPNG RCLNTVPGYV CLCNPGFHYD ASHKKCEDHD ECQDLACENG ECVNTEGSFH CFCSPPLTLD LSQQRCMNST SSTEDLPDHD IHMDICWKKV TNDVCSEPLR GHRTTYTECC CQDGEAWSQQ CALCPPRSSE VYAQLCNVAR IEAEREAGVH FRPGYEYGPG PDDLHYSIYG PDGAPFYNYL GPEDTVPEPA FPNTAGHSAD RTPILESPLQ PSELQPHYVA SHPEPPAGFE GLQAEECGIL NGCENGRCVR VREGYTCDCF EGFQLDAAHM ACVDVNECDD LNGPAVLCVH GYCENTEGSY RCHCSPGYVA EAGPPHCTAK E //